PT3280440T - Anticorpos anti-c1s humanizados e métodos de utilização destes - Google Patents

Anticorpos anti-c1s humanizados e métodos de utilização destes

Info

Publication number
PT3280440T
PT3280440T PT167771344T PT16777134T PT3280440T PT 3280440 T PT3280440 T PT 3280440T PT 167771344 T PT167771344 T PT 167771344T PT 16777134 T PT16777134 T PT 16777134T PT 3280440 T PT3280440 T PT 3280440T
Authority
PT
Portugal
Prior art keywords
antibodies
methods
humanized anti
humanized
Prior art date
Application number
PT167771344T
Other languages
English (en)
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of PT3280440T publication Critical patent/PT3280440T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21106—Hepsin (3.4.21.106)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PT167771344T 2015-04-06 2016-04-05 Anticorpos anti-c1s humanizados e métodos de utilização destes PT3280440T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562143636P 2015-04-06 2015-04-06
US201562200997P 2015-08-04 2015-08-04

Publications (1)

Publication Number Publication Date
PT3280440T true PT3280440T (pt) 2023-02-14

Family

ID=57073330

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167771344T PT3280440T (pt) 2015-04-06 2016-04-05 Anticorpos anti-c1s humanizados e métodos de utilização destes

Country Status (27)

Country Link
US (3) US10729767B2 (pt)
EP (2) EP4212175A1 (pt)
JP (3) JP7005483B2 (pt)
KR (1) KR20180006379A (pt)
CN (2) CN108348598B (pt)
AU (2) AU2016246452B2 (pt)
BR (1) BR112017021289A2 (pt)
CA (1) CA2981321A1 (pt)
CL (1) CL2017002514A1 (pt)
CO (1) CO2017011238A2 (pt)
DK (1) DK3280440T3 (pt)
EA (1) EA201792080A1 (pt)
ES (1) ES2938359T3 (pt)
FI (1) FI3280440T3 (pt)
HK (2) HK1250930A1 (pt)
HR (1) HRP20230093T1 (pt)
HU (1) HUE061076T2 (pt)
IL (2) IL254670B2 (pt)
LT (1) LT3280440T (pt)
MX (2) MX2017012834A (pt)
PH (1) PH12017501815A1 (pt)
PL (1) PL3280440T3 (pt)
PT (1) PT3280440T (pt)
RS (1) RS63956B1 (pt)
SG (2) SG10201909180SA (pt)
SI (1) SI3280440T1 (pt)
WO (1) WO2016164358A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
PE20191031A1 (es) * 2016-10-12 2019-08-05 Bioverativ Usa Inc ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS
CN112313249A (zh) * 2018-04-13 2021-02-02 中外制药株式会社 抗补体组分抗体及使用方法
KR20230044312A (ko) 2020-08-06 2023-04-03 바이오버라티브 유에스에이 인코포레이티드 보체 매개된 질환을 갖는 대상체의 염증성 시토카인 및 피로
CN117241828A (zh) 2021-03-31 2023-12-15 美国比奥维拉迪维股份有限公司 减少冷凝集素病患者的手术相关溶血
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof
WO2023245048A1 (en) 2022-06-15 2023-12-21 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
US20240025978A1 (en) 2022-06-24 2024-01-25 Bioverativ Usa Inc. Methods for treating complement-mediated diseases

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
AU678064B2 (en) 1993-09-01 1997-05-15 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Method to reduce myocardial injury during acute myocardial infarction
ATE437232T1 (de) 1993-10-25 2009-08-15 Canji Inc Rekombinanter adenoviren-vektor und verfahren zur verwendung
CN1160469C (zh) 1994-12-09 2004-08-04 帝国大学改革有限公司 基因的鉴定
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
AU3998400A (en) 1999-02-09 2000-08-29 3-Dimensional Pharmaceuticals, Inc. Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
WO2000064327A2 (en) 1999-04-26 2000-11-02 Duke University Inhibition of complement action
AU6929100A (en) 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
WO2001057079A2 (en) 2000-01-31 2001-08-09 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
ES2329010T3 (es) 2000-03-23 2009-11-20 Genentech, Inc. Inhibidores anti-c2/c2a de la activacion del complemento.
CA2413830A1 (en) 2000-06-21 2001-12-27 Zymogenetics, Inc. Peptide and polypeptide inhibitors of complement c1s
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
JP2004536138A (ja) 2001-07-26 2004-12-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 認識機能を改善する方法
US20080206242A1 (en) * 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
SE0202880D0 (sv) 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP1545611B1 (en) 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
AU2004241069B2 (en) 2003-05-15 2010-09-09 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
WO2005035754A1 (ja) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
EP1697741A4 (en) * 2003-12-04 2008-02-13 Xencor Inc PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
LT1753456T (lt) 2004-06-10 2016-11-10 Omeros Corporation Ligų, susijusių su nuo masp-2 priklausomu komplemento aktyvinimu, gydymo būdai
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2005123776A1 (en) 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1819731A4 (en) 2004-12-08 2013-02-13 Immunomedics Inc METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
WO2006101860A1 (en) 2005-03-16 2006-09-28 Janssen Pharmaceutica N.V. Novel thiophene sulfoximines for treating complement-mediated diseases and conditions
EP2529746A1 (en) 2005-06-06 2012-12-05 Girish J. Kotwal Methods for treatment or prophylaxis of reperfusion injury
KR101393946B1 (ko) 2005-10-21 2014-05-12 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8148330B2 (en) 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
AU2006327989B2 (en) 2005-12-21 2012-06-07 Pharming Intellectual Property Bv Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
FR2897868B1 (fr) 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
CA3148917A1 (en) 2006-03-08 2007-09-13 Archemix Llc Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
PL2061810T3 (pl) 2006-09-05 2015-05-29 Alexion Pharma Inc Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał
PL2698166T3 (pl) 2006-10-10 2016-03-31 Regenesance B V Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
WO2008074227A1 (en) 2006-12-19 2008-06-26 Versitech Limited Synthetic ion channels
EP2979729A3 (en) 2007-02-05 2016-05-11 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
PE20140614A1 (es) 2007-07-16 2014-05-28 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
AU2008299779B2 (en) 2007-08-03 2013-05-16 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
AU2009239437B2 (en) 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
WO2009151634A1 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
AU2009313203B2 (en) 2008-11-10 2015-08-27 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
AU2009322607B2 (en) 2008-12-01 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20110002931A1 (en) 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JP5911804B2 (ja) 2009-10-16 2016-04-27 オメロス コーポレーション Ｍａｓｐ−２依存性の補体活性化を阻害することによって播種性血管内凝固を処置するための方法
US8883985B2 (en) 2010-02-16 2014-11-11 National University Corporation Kyoto Institute Of Technology Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier
RU2570390C2 (ru) 2010-03-01 2015-12-10 Алексион Фармасьютикалз Инк. Способы и композиции для лечения болезни дего
SG185383A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
CA2799746C (en) 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
KR20130036276A (ko) 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 보체 결합 3의 C3d 조각에 대한 항체들
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
WO2012078688A2 (en) 2010-12-06 2012-06-14 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
KR20220044616A (ko) 2011-04-08 2022-04-08 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
EP2704743B1 (en) 2011-05-04 2020-03-11 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
JP6127063B2 (ja) 2011-12-22 2017-05-10 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
JP6081699B2 (ja) 2011-12-28 2017-02-15 雅史 溝上 Ｉｌ−２８ｂの分析方法
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
RS63212B1 (sr) * 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
KR101638931B1 (ko) 2013-01-31 2016-07-12 서울대학교산학협력단 보체 관련 질환의 예방 및 치료를 위한 ｃ5 항체 및 방법
EP3019240B1 (en) 2013-07-09 2024-03-13 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
WO2015084999A1 (en) 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
KR20180020296A (ko) 2015-06-26 2018-02-27 바이오버라티브 유에스에이 인코포레이티드 자가면역 및 동종면역 장애를 치료하는 방법
PE20191031A1 (es) 2016-10-12 2019-08-05 Bioverativ Usa Inc ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS
CA3055781A1 (en) 2017-03-14 2018-09-20 Bioverativ Usa Inc. Methods for treating complement-mediated diseases and disorders

Also Published As

Publication number Publication date
ES2938359T3 (es) 2023-04-10
MX2017012834A (es) 2018-05-28
JP2021006544A (ja) 2021-01-21
US20200405852A1 (en) 2020-12-31
WO2016164358A1 (en) 2016-10-13
DK3280440T3 (da) 2023-02-20
EP3280440A1 (en) 2018-02-14
HUE061076T2 (hu) 2023-05-28
AU2016246452A1 (en) 2017-10-19
EP3280440A4 (en) 2018-08-29
CA2981321A1 (en) 2016-10-13
CO2017011238A2 (es) 2018-01-16
LT3280440T (lt) 2023-02-27
HRP20230093T1 (hr) 2023-03-31
AU2022203679A1 (en) 2022-06-16
CN117285634A (zh) 2023-12-26
US11246926B2 (en) 2022-02-15
US10729767B2 (en) 2020-08-04
JP2022078221A (ja) 2022-05-24
EA201792080A1 (ru) 2018-03-30
IL254670B (en) 2022-12-01
PL3280440T3 (pl) 2023-06-19
JP2018513213A (ja) 2018-05-24
PH12017501815A1 (en) 2018-04-23
HK1259251A1 (zh) 2019-11-29
EP4212175A1 (en) 2023-07-19
EP3280440B1 (en) 2022-11-16
FI3280440T3 (fi) 2023-03-09
SG11201707886WA (en) 2017-10-30
CN108348598A (zh) 2018-07-31
MX2022001085A (es) 2022-02-14
AU2016246452B2 (en) 2022-03-10
IL254670B2 (en) 2023-04-01
US20230218753A1 (en) 2023-07-13
HK1250930A1 (zh) 2019-01-18
KR20180006379A (ko) 2018-01-17
JP7005483B2 (ja) 2022-02-10
CL2017002514A1 (es) 2018-04-20
IL254670A0 (en) 2017-11-30
US20180092974A1 (en) 2018-04-05
BR112017021289A2 (pt) 2018-06-26
JP7153696B2 (ja) 2022-10-14
CN108348598B (zh) 2023-09-01
SG10201909180SA (en) 2019-11-28
IL298180A (en) 2023-01-01
RS63956B1 (sr) 2023-02-28
SI3280440T1 (sl) 2023-03-31

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
HK1258058A1 (zh) 抗tigit抗體和使用方法
HK1250513A1 (zh) 抗ox40抗體及其使用方法
HK1252858A1 (zh) 抗cll-1抗體和使用方法
HK1249445A1 (zh) 抗分揀蛋白抗體和其使用方法
HK1252698A1 (zh) 抗siglec-9抗體及其使用方法
HK1252696A1 (zh) 抗siglec-7抗體及其使用方法
HK1251969A1 (zh) 抗her2抗體和使用方法
HK1259251A1 (zh) 人源化抗c1s抗體及其使用方法
HK1256094A1 (zh) 抗-htra1抗體及其使用方法
HK1258850A1 (zh) 抗tpbg抗體及使用方法